Please assess the completion status of the following clinical trial:

Trial Title: Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have histologically confirmed diagnosis of esophageal cancer without prior palliative treatment or an interval of at least 6 months from the last operation, adjuvant radiation therapy and adjuvant chemotherapy. If patients received adjuvant chemotherapy, paclitaxel and cisplatin must be excluded from the regiment or the total dosage of cisplatin must be less than 300mg/m2.~* - Patients must be 18 to 75 years old and both genders are eligible.~* - Patients must have measurable or evaluable disease with at least one tumor mass maximum diameter ≥10mm by multi-slice spiral CT or MR scan. If ordinary CT scan is used the tumor mass maximum diameter must ≥ 2cm. Imaging exam must be performed within 15 days from enrollment.~* - Patients must have an expected life expectancy of ≥ 3 months~* - Patients must have a performance status of ≥ 80 on the Karnofsky scale~* - Patients must have normal marrow function and the blood tests must be collected within 7 days from enrollment with a hemoglobin (HGB) of ≥90g/L, an white blood cell (WBC) counts of ≥4.0×109/L，a neutrophil count of ≥2.0×109/L, , a platelet count of ≥100×109/L, a total bilirubin (TBil) of ≤1.0 upper normal limitation (UNL), a creatinine (Cr) of ≤ 1.0 UNL, alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤2.5 UNL, Alkaline phosphatase (AKP) ≤5.0 UNL. For patients with liver metastasis, the ASAT/ALAT must be ≤5.0 UNL.~* - Patients must have normal electrocardiogram results and no history of congestive heart failure.~* - Patients must be with good compliance and agree to accept follow-up of disease progression and adverse events.~* - Patients must give written informed consent signed voluntarily by patients themselves or their supervisors witted by doctors~Exclusion Criteria:~* Patients who have received prior palliative treatment or less than 6 months from the last operation, adjuvant radiotherapy, adjuvant chemotherapy.~* Previous treatment regiment involve paclitaxel and S-1~* Tumor mass \>10mm by CT or MR scan. The total area of metastatic tumor lesions in liver is over 50% of whole liver or the total area of metastatic tumor lesions in lung is over 25% of whole lung.~* Patients without measurable or evaluable disease, for example cavity effusion or diffusive metastasis of organs.~* Patients with history of other tumors except for those of cervical carcinoma in situ or skin basal cell carcinoma who had been completely treated and without relapse in last 5 years.~* Patients with serious diseases such as congestive heart failure, uncontrolled myocardial infarction and arrhythmia, liver failure and renal failure.~* Patients with only brain metastasis or bone metastasis~* Patients with chronic diarrhea~* Patients with neurological or psychiatric abnormalities including metastasis of the central nervous system that affect cognitive.~* Pregnant or lactated women (premenopausal women must give urine pregnancy test before enrollment).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- S-1 and Paclitaxel (Type: EXPERIMENTAL): Patients in these arm will receive combination treatment of S-1 and paclitaxel. S-1, 80-120mg po, bid, from day 1 to day 14 Paclitaxel, 175mg/m2, IV infusion on day 1 Repeated every 21 days
- Paclitaxel and Cisplatin (Type: ACTIVE_COMPARATOR): Patients in these arm will receive combination treatment of paclitaxel and cisplatin.~Paclitaxel, 175mg/m2, IV infusion on day 1 Cisplatin, 30 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days
- 5-FU and Cisplatin (Type: ACTIVE_COMPARATOR): Patients in these arm will receive combination treatment of 5-FU and cisplatin. 5-FU, 2500mg/m2, continue iv infusion for 120 hours Cisplatin, 35 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues